Dr. Michel B Chonchol, MD
Claim this profileUColorado
Studies High Blood Pressure
Studies Chronic Kidney Disease
4 reported clinical trials
6 drugs studied
Area of expertise
1High Blood Pressure
Stage III
Stage IV
2Chronic Kidney Disease
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Michel B Chonchol, MD is currently running
Nicotinamide Riboside
for Kidney Disease
Risk of cardiovascular diseases (CVD) is significantly elevated in patients with chronic kidney disease (CKD); however, this increased risk is only partially explained by traditional CV risk factors. Arterial dysfunction is an important nontraditional CV risk factor gaining increased recognition in the field of nephrology. This process is best represented, both physiologically and pathophysiologically, by increases in the gold standard measure of arterial stiffening, carotid to femoral artery pulse wave velocity (CFPWV), which reflects, in particular, increases in aortic stiffness. Aortic stiffening with CKD is mediated by structural and functional (increased vascular smooth muscle tone) changes in the arterial wall stimulated by oxidative stress and chronic low-grade inflammation. Caloric restriction (CR) is a promising strategy for prevention of CKD-associated arterial dysfunction and CVD. However, long-term adherence to chronic CR regimens with optimal nutrition is very difficult to achieve. Research has shown that boosting NAD+ bioavailability to stimulate SIRT-1, a "CR mimetic" approach, reduces CFPW and oxidative stress in old mice, and this lab recently took the first step in translating these findings in a study of adults with normal kidney function and elevated systolic blood pressure (SBP). The data found that supplementation with nicotinamide riboside, a natural, commercially available precursor of NAD+ and novel CR mimetic, increased NAD+ bioavailability and reduced CFPWV and SBP. A randomized, placebo-controlled, double-blind, single-site phase IIa clinical trial to assess the safety and efficacy of oral nicotinamide riboside (500 mg capsules 2x/day; NIAGEN®; ChromaDex Inc.) for 3 months vs. placebo for decreasing aortic stiffness and SBP in patients (35-80 years) with stage III and IV CKD is being proposed. It is hypothesized that treatment will reduce CFPWV and SBP, as related to increases in systemic NAD+ bioavailability and reductions in oxidative stress, and inflammation. Aim 1: To measure CFPWV (primary outcome) before/after nicotinamide riboside vs. placebo treatment; Aim 2: To measure casual and 24h-ambulatory SBP (secondary outcome) before and after treatment; Aim 3: To determine the safety and tolerability of treatment with nicotinamide riboside vs. placebo; Aim 4: To measure systemic NAD+ and NAD+-related metabolite concentrations, as well as circulating markers of oxidative stress, inflammation, and vasoconstriction factors before and after treatment.
Recruiting0 awards Phase 27 criteria
IMST
for Chronic Kidney Disease and High Blood Pressure
More than 80% of individuals with chronic kidney disease have concomitant hypertension and the majority fail to achieve blood pressure control \<130/80 mmHg, leading to high risk of cardiovascular diseases and end-stage kidney disease. A stepwise combination of lifestyle modifications and drug therapy is recommended to lower blood pressure; however, adherence to time-intensive lifestyle interventions such as aerobic exercise in patients with chronic kidney disease is poor. This clinical trial seeks to establish the efficacy of high-resistance inspiratory muscle strength training, a novel time-efficient lifestyle intervention, for lowering systolic blood pressure and improving endothelial function in midlife and older adults with moderate-to-severe chronic kidney disease and inadequately controlled hypertension, and to use innovate translational assessments to understand the mechanisms involved.
Recruiting0 awards N/A5 criteria
More about Michel B Chonchol, MD
Clinical Trial Related8 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michel B Chonchol, MD has experience with
- Placebo
- IMST
- Sham Training
- Nicotinamide Riboside
- Empagliflozin
- Pravastatin
Breakdown of trials Michel B Chonchol, MD has run
High Blood Pressure
Chronic Kidney Disease
Polycystic Kidney Disease
Vascular Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michel B Chonchol, MD specialize in?
Michel B Chonchol, MD focuses on High Blood Pressure and Chronic Kidney Disease. In particular, much of their work with High Blood Pressure has involved Stage III patients, or patients who are Stage IV.
Is Michel B Chonchol, MD currently recruiting for clinical trials?
Yes, Michel B Chonchol, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Michel B Chonchol, MD has studied deeply?
Yes, Michel B Chonchol, MD has studied treatments such as Placebo, IMST, Sham Training.
What is the best way to schedule an appointment with Michel B Chonchol, MD?
Apply for one of the trials that Michel B Chonchol, MD is conducting.
What is the office address of Michel B Chonchol, MD?
The office of Michel B Chonchol, MD is located at: UColorado, Aurora, Colorado 80045 United States. This is the address for their practice at the UColorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.